Antibiotics and Staphylococcus aureus - More than meets the MIC

Journal of Molecular Medicine

Volumn 92, Issue 2, 2014, Pages 103-106

  Howden, Benjamin P ^a,b,c,d  

^a AUSTIN HEALTH   (Australia)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84894039726     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-013-1113-2     Document Type: Article

References (12)

1. Lowy FD (1998) Staphylococcus aureus infections. NEJM 339:520-532
2. Lindsay JA (2010) Genomic variation and evolution of Staphylococcus aureus. Int J Med Microbiol: IJMM 300:98-103
3. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, Lessa FC, Lynfield R, Nadle J, Petit S et al (2013) National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Int Med 173:1970-1978
4. Peschel A, Sahl HG (2006) The co-evolution of host cationic antimicrobial peptides and microbial resistance. Nat Rev Microbiol 4:529-536
5. Nijnik A, Hancock R (2009) Host defence peptides: antimicrobial and immunomodulatory activity and potential applications for tackling antibiotic-resistant infections. Emerg Health Threats J 2:e1
6. Hilchie AL, Wuerth K, Hancock RE (2013) Immune modulation by multifaceted cationic host defense (antimicrobial) peptides. Nat Chem Biol 9:761-768
7. Hancock RE, Sahl HG (2006) Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 24:1551-1557
8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis: Off Publ Infect Dis Soc Am 48:1-12
9. Sakoulas GOC, Thienphrapa W, Olson J, Nonejuie P, Dam Q, Dhand A, Pogliano J, Yeaman MR, Hensler ME, Bayer AS et al (2013) Nafcillin enhances innate immune-mediated killing of methicillin resistant Staphylococcus aureus. J Mol Med. doi: 10.1007/s00109-013-1100-7
10. Dhand A, Bayer AS, Pogliano J, Yang SJ, Bolaris M, Nizet V, Wang G, Sakoulas G (2011) Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53:158-163
11. Sakoulas G, Bayer AS, Pogliano J, Tsuji BT, Yang SJ, Mishra NN, Nizet V, Yeaman MR, Moise PA (2012) Ampicillin enhances daptomycin - and cationic host defense peptide-mediated killing of ampicillin - and vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 56:838-844
12. Dilworth TJ, Ibrahim O, Hall P, Sliwinski J, Walraven C, Mercier RC (2013) Beta-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomcyin alone. Antimicrob Agents Chemother. Epub. In Press